Lyell Immunopharma, Inc. (LYEL)
NASDAQ: LYEL · IEX Real-Time Price · USD
1.525
-0.035 (-2.24%)
Jul 22, 2024, 10:07 AM EDT - Market open
Lyell Immunopharma Employees
Lyell Immunopharma had 224 employees as of December 31, 2023. The number of employees decreased by 50 or -18.25% compared to the previous year.
Employees
224
Change (1Y)
-50
Growth (1Y)
-18.25%
Revenue / Employee
$304
Profits / Employee
-$1,019,375
Market Cap
402.80M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 224 | -50 | -18.25% |
| Dec 31, 2022 | 274 | 55 | 25.11% |
| Dec 31, 2021 | 219 | 29 | 15.26% |
| Dec 31, 2020 | 190 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Organogenesis Holdings | 862 |
| Cerus | 637 |
| Revance Therapeutics | 597 |
| AxoGen | 428 |
| Esperion Therapeutics | 240 |
| Sight Sciences | 214 |
| Precigen | 202 |
| Tourmaline Bio | 44 |
LYEL News
- 26 days ago - Lyell Immunopharma Reports Dose-dependent Clinical Activity from Phase 1 Trial of LYL797, a ROR1-targeted CAR-T Cell Product Candidate Enhanced with its Proprietary Anti-exhaustion Technology - GlobeNewsWire
- 6 weeks ago - Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference - GlobeNewsWire
- 2 months ago - Lyell Immunopharma to Participate in BofA Securities Health Care Conference - GlobeNewsWire
- 2 months ago - Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024 - GlobeNewsWire
- 4 months ago - Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual Meeting - GlobeNewsWire
- 5 months ago - Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023 - GlobeNewsWire
- 5 months ago - Lyell Immunopharma Announces Participation in March Investor Conferences - GlobeNewsWire
- 7 months ago - Lyell Immunopharma to Participate in 42nd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire